{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T15:05:16Z","timestamp":1775315116394,"version":"3.50.1"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,12,6]],"date-time":"2018-12-06T00:00:00Z","timestamp":1544054400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Research Deputy of Islamic Azad University, Tehran Medical Sciences, Tehran, Iran","award":["39003"],"award-info":[{"award-number":["39003"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["IBRO Reports"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1016\/j.ibror.2018.12.001","type":"journal-article","created":{"date-parts":[[2018,12,14]],"date-time":"2018-12-14T14:52:35Z","timestamp":1544799155000},"page":"40-44","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["Anti-dyskinetic efficacy of 5-HT3 receptor antagonist in the hemi-parkinsonian rat model"],"prefix":"10.1016","volume":"6","author":[{"given":"Nazanin","family":"Aboulghasemi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahsa","family":"Hadipour Jahromy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3920-9234","authenticated-orcid":false,"given":"Amir","family":"Ghasemi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ibror.2018.12.001_bib0005","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1146\/annurev.med.60.042307.110802","article-title":"The expanded biology of serotonin\"","volume":"60","author":"Berger","year":"2009","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.ibror.2018.12.001_bib0010","doi-asserted-by":"crossref","first-page":"2839","DOI":"10.1111\/j.1460-9568.2012.08202.x","article-title":"Serotonin transporter inhibition attenuates L-DOPA-induced dyskinesia without compromising levodopa efficacy in hemiparkinsonian rats","volume":"36","author":"Bishop","year":"2012","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.ibror.2018.12.001_bib0015","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1038\/sj.npp.1301294","article-title":"Endogenous serotonin excites striatal cholinergic interneurons via the activation of 5-HT 2C, 5-HT6, and 5-HT7 serotonin receptors: implications for extrapyramidal Side effects of serotonin reuptake inhibitors","volume":"32","author":"Bonsi","year":"2007","journal-title":"Neuropsychopharmacology."},{"key":"10.1016\/j.ibror.2018.12.001_bib0020","doi-asserted-by":"crossref","first-page":"8011","DOI":"10.1523\/JNEUROSCI.2079-07.2007","article-title":"Serotonin neuron transplants exacerbate leodopa induced dyskinesias in a rat model of parkinson\u2019s disease","volume":"27","author":"Carlsson","year":"2007","journal-title":"J. Neurosci."},{"key":"10.1016\/j.ibror.2018.12.001_bib0025","doi-asserted-by":"crossref","first-page":"78","DOI":"10.3389\/fneur.2014.00078","article-title":"Serotonin system implication in L-DOPA-induced dyskinesia: from animal models to clinical investigations","volume":"5","author":"Carta","year":"2014","journal-title":"Front Neurol."},{"key":"10.1016\/j.ibror.2018.12.001_bib0030","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1093\/brain\/awm082","article-title":"Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats","volume":"130","author":"Carta","year":"2007","journal-title":"Brain."},{"key":"10.1016\/j.ibror.2018.12.001_bib0035","first-page":"61","article-title":"Serotonin\u2013dopamine interaction in the induction and maintenance of L-DOPA-induced dyskinesias","volume":"172","author":"Carta","year":"2008","journal-title":"Progress Brain Res."},{"key":"10.1016\/j.ibror.2018.12.001_bib0040","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1111\/j.1476-5381.1987.tb11394.x","article-title":"Tyers MB: effects of the 5-HT3 receptor antagonist, GR38032F, on raised dopaminergic activity in the mesolimbic system of the rat and marmoset brain","volume":"92","author":"Costall","year":"1987","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ibror.2018.12.001_bib0045","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/0163-7258(90)90086-H","article-title":"The psychopharmacology of 5-HT3 receptors","volume":"47","author":"Costall","year":"1990","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ibror.2018.12.001_bib0050","first-page":"39","article-title":"Ranitidine reduced levodopa-induced dyskinesia in a rat model of parkinson\u2019s disease","volume":"10","author":"Cui","year":"2014","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"10.1016\/j.ibror.2018.12.001_bib0055","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1097\/00000441-199212000-00009","article-title":"Ondansetron: pharmacology of a specific 5-HT3 receptor antagonist","volume":"304","author":"Deegan","year":"1992","journal-title":"Ame J. Med. Sci."},{"key":"10.1016\/j.ibror.2018.12.001_bib0060","doi-asserted-by":"crossref","first-page":"165","DOI":"10.2174\/138945006775515491","article-title":"Modulation of dopamine transmission by 5-HT2 and 5-HT3 receptors","volume":"7","author":"Dremencove","year":"2006","journal-title":"Curr. Drug Targets"},{"key":"10.1016\/j.ibror.2018.12.001_bib0065","first-page":"1","article-title":"Clinical features, pathophysiology, and treatment of levodopa-induced dyskinesias in Parkinson\u2019s disease","volume":"10","author":"Guridi","year":"2012","journal-title":"Parkinson\u2019s Dis."},{"issue":"1","key":"10.1016\/j.ibror.2018.12.001_bib0070","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.bbr.2008.03.020","article-title":"Molecular biology of 5-HT receptors","volume":"195","author":"Hannon","year":"2008","journal-title":"Behav. Brain Res."},{"issue":"2","key":"10.1016\/j.ibror.2018.12.001_bib0075","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.bbrc.2005.07.079","article-title":"Cloning and expression of ligand-gated ion channel receptor L2 in central nervous system","volume":"335","author":"Houtani","year":"2005","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ibror.2018.12.001_bib0080","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1124\/jpet.106.110429","article-title":"In MPTP treated primates, the selective 5-HT1a agonist (R)-(+)-8-hydroxy-DPAT inhibits levodopainduced dyskinesia but only with increased motor disability","volume":"319","author":"Iravani","year":"2006","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ibror.2018.12.001_bib0085","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0062515","article-title":"Differences in dopaminergic modulation to motor cortical plasticity between Parkinson\u2019s disease and multiple system atrophy","volume":"8","author":"Kawashima","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.ibror.2018.12.001_bib0090","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/bph.12894","article-title":"Side effect profile of 5-HT treatments for Parkinson\u2019s disease and L-DOPA-induced dyskinesia in rats","volume":"172","author":"Lindenbach","year":"2015","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ibror.2018.12.001_bib0095","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.expneurol.2005.02.002","article-title":"Pharmacological validation of a mouse model of l-DOPA-induced dyskinesia","volume":"194","author":"Lundblad","year":"2005","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.ibror.2018.12.001_bib0100","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1056\/NEJM199003223221205","article-title":"Comparison of the 5-hydroxytryptamine (serotonin) antagonist ondansetron (GR 38032F) with high-dose metoclopramide in the control of cisplatin-induced emesis","volume":"332","author":"Marty","year":"1990","journal-title":"N. Eng. J. Med."},{"key":"10.1016\/j.ibror.2018.12.001_bib0105","doi-asserted-by":"crossref","first-page":"3380","DOI":"10.1093\/brain\/awn235","article-title":"Combined 5-HT1A and5-HT1B receptor agonists for the treatment of l-DOPA-induced dyskinesia","volume":"131","author":"Munoz","year":"2008","journal-title":"Brain"},{"issue":"2-3","key":"10.1016\/j.ibror.2018.12.001_bib0110","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s00213-010-2029-y","article-title":"Presynaptic control of serotonin on striatal dopamine function","volume":"213","author":"Navailles","year":"2011","journal-title":"Psychopharmacology (Berl)."},{"key":"10.1016\/j.ibror.2018.12.001_bib0115","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.neuropharm.2010.08.019","article-title":"Serotonergic modulation of extrapyramidal motor disorders in mice and rats: role of striatal 5-HT3 and 5-HT6 receptors","volume":"60","author":"Ohno","year":"2011","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.ibror.2018.12.001_bib0120","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.neuropharm.2010.08.019","article-title":"Serotonergic modulation of extrapyramidal motor disorders in mice and rats: role of striatal 5-HT3 and 5-HT6 receptors","volume":"60","author":"Ohno","year":"2011","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.ibror.2018.12.001_bib0125","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1248\/bpb.b13-00310","article-title":"Recent advances in 5-hydroxytryptamine (5-HT) receptor research: how many pathophysiological roles does 5-HT play via its multiple receptor subtypes?","volume":"36","author":"Ohno","year":"2013","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.ibror.2018.12.001_bib0130","doi-asserted-by":"crossref","DOI":"10.1248\/bpb.b13-00310","article-title":"Pathophysiological roles of serotonergic system in regulating extrapyramidal motor functions","volume":"36","author":"Ohno","year":"2013","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.ibror.2018.12.001_bib0135","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.pneurobio.2015.09.005","article-title":"New insight into the therapeutic role of the serotonergic system in Parkinson\u2019s disease","volume":"134","author":"Ohno","year":"2015","journal-title":"Prog Neurobiol."},{"key":"10.1016\/j.ibror.2018.12.001_bib0140","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1172\/JCI71640","article-title":"Serotonergic mechanisms responsible for levodopa-induced dyskinesias in Parkinson\u2019s disease patients","volume":"124","author":"Politis","year":"2014","journal-title":"J Clin Invest."},{"key":"10.1016\/j.ibror.2018.12.001_bib0145","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1176\/appi.ajp.157.2.287","article-title":"Use of the selective serotonin 3 receptor antagonist ondansetron in the treatment of neuroleptic-induced tardive dyskinesia","volume":"157","author":"Sirota","year":"2000","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.ibror.2018.12.001_bib0150","first-page":"75","article-title":"Levodopaand brain serotonin system dysfunction","volume":"3","author":"Stansley","year":"2015","journal-title":"Toxicology"},{"key":"10.1016\/j.ibror.2018.12.001_bib0155","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1016\/S0022-3565(25)39339-0","article-title":"Characterization of typical and atypical antipsychotic drugs based on in-vivo occupancy of serotonin2 and dopamine2 receptors","volume":"266","author":"Stockmeier","year":"1993","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ibror.2018.12.001_bib0160","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.pbb.2008.04.010","article-title":"A 5-HT2A receptor inverse agonist, ACP-103, reduces tremor in a rat model and levodopa-induced dyskinesias in a monkey model","volume":"90","author":"Vanover","year":"2008","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.ibror.2018.12.001_bib0165","first-page":"341","article-title":"Levodopa\/benserazide microspheres reduced levodopa-induced dyskinesia by downregulating phosphorylated GluR1 expression in 6-OHDA-lesioned rats","volume":"6","author":"Yang","year":"2012","journal-title":"Drug design Dev. Ther."},{"issue":"July","key":"10.1016\/j.ibror.2018.12.001_bib0170","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1212\/WNL.45.7.1305","article-title":"Psychosis in advanced parkinson\u2019s disease treatment with ondansetron, a 5\u2010HT3 receptor antagonist","volume":"45","author":"Zoldan","year":"1995","journal-title":"Neurology"}],"container-title":["IBRO Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2451830118300645?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2451830118300645?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T14:08:01Z","timestamp":1775311681000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2451830118300645"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":34,"alternative-id":["S2451830118300645"],"URL":"https:\/\/doi.org\/10.1016\/j.ibror.2018.12.001","relation":{},"ISSN":["2451-8301"],"issn-type":[{"value":"2451-8301","type":"print"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anti-dyskinetic efficacy of 5-HT3 receptor antagonist in the hemi-parkinsonian rat model","name":"articletitle","label":"Article Title"},{"value":"IBRO Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ibror.2018.12.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier Ltd on behalf of International Brain Research Organization.","name":"copyright","label":"Copyright"}]}}